Exact Sciences Corporation

NASDAQ•EXAS

CEO: Mr. Kevin T. Conroy J.D.

セクター: Healthcare

業種: Medical - Diagnostics & Research

上場日: 2001-02-01

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

連絡先情報

5505 Endeavor Lane, Madison, WI, 53719, United States

608-284-5700

www.exactsciences.com

時価総額

$19.77B

PER (TTM)

-94.5

19.3

配当利回り

52週高値

$103.75

52週安値

$38.81

52週レンジ

100%

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$878.38M+0.00%

直近4四半期の推移

EPS

-$0.45+0.00%

直近4四半期の推移

フリーCF

$120.45M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Revenue Grew 17.7% Total revenue reached $3.25B USD in 2025, driven by 20.2% growth in Screening revenue segment.

Net Loss Significantly Narrowed Net loss reduced to $207.9M USD in 2025, a substantial improvement from $1.03B USD loss last year.

Operating Cash Flow Improved Cash provided by operating activities was $491.4M USD, reflecting a $280.9M USD improvement over 2024.

Abbott Merger Agreement Signed Entered Merger Agreement with Abbott for $105.00 cash per share; expected consummation in Q2 2026.

リスク要因

Merger Execution Uncertainty Failure or delay in closing the Abbott Merger could materially affect operations and common stock price.

Dependence on Product Success Success heavily relies on commercialization of Screening and Precision Oncology tests in development pipeline.

Regulatory and Reimbursement Risks Uncertainty exists related to healthcare reform, pricing, coverage, and maintaining adequate reimbursement rates.

Need for Additional Capital Additional capital may be required to fully fund strategic plan; financing availability or terms are uncertain.

見通し

Productivity Plan Implementation Implementing multi-year productivity plan targeting over $150M USD in expected annual savings by 2026.

Pipeline Development Investment Expect continued significant investment in R&D to enhance current products and advance pipeline offerings.

Next-Generation MRD Test Launch Plan to introduce next-generation Oncodetect MRD test leveraging MAESTRO technology in 2026.

International Expansion Exploration Exploring opportunities to make Cologuard and Cancerguard tests available outside the U.S. market soon.

同業比較

売上高 (TTM)

VTRS

$14.30B

-3.0%

BAX

$11.24B

+5.7%

ICLR

$8.10B

-2.5%

粗利益率 (最新四半期)

IONS

96.1%

-0.7pp

BBIO

90.0%

+16.5pp

DOCS

89.9%

+0.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ROIV	$20.08B	-24.2	-18.3%	4.0%
EXAS	$19.77B	-94.5	-8.5%	43.0%
RVMD	$18.80B	-15.9	-63.1%	6.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

7.5%

安定成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

100%

優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし